Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, 2-part, open-label, fixed-sequence study evaluating the effect of rifampin
(part 1) and rabeprazole (part 2) on the pharmacokinetics of a single dose of camlipixant
(BLU-5937) 50 mg tablet in healthy participants under fasting conditions.